Regulatory mechanisms of LGR4 on cancer and cancer stem cell properties Authors: Jialei Yang, Jinye Zhao, Houchang Liu, Saili Luo, Jialun Hu, Yunhua Pan Published: 2026 ABSTRACT Leucine-rich repeats containing G protein-coupled receptor 4 (LGR4) is a receptor belonging to the G-protein-coupled receptor superfamily. LGR4 can be activated by ligands such as R-spondins (RSPOs), Norrin, and the ligand of the receptor activator of nuclear factor kappa-B(RANKL) to regulate signaling pathways in both normal and pathological processes. LGR4 is widely expressed across various tissues and serves multiple functions, including organ development and maintenance, primarily regulating cell proliferation, survival, and differentiation through the Wnt/β-catenin pathway. In tumors, LGR4 is involved in the progression, invasion, and metastasis of various cancers, including colorectal, breast, prostate, lung, and skin cancers. Recent studies indicate that LGR4 plays a crucial role in regulating tumor stem cell populations by modulating their self-renewal capabilities and regulating stem cell characteristics. This review discusses the expression and functional roles of LGR4 in tumors, the molecular mechanisms regulated by LGR4, and the relationship between LGR4, tumor stem cells, and chemotherapy resistance. Introduction Most cancer-related deaths are attributed to tumor recurrence or metastasis. Consequently, it is essential to gain a comprehensive understanding of the cellular and molecular mechanisms that contribute to cancer recurrence and dissemination. Cancer stem cells (CSCs), also known as tumor-initiating cells, represent a small population of cells within tumors that possess self-renewal and differentiation potential. These cells are highly tumorigenic and play a critical role in tumor progression, chemotherapy resistance, and recurrence [1, 2]. CSCs possess unique capabilities of self-renewal and differentiation, forming a diverse cell population within tumors, sustaining tumor growth, and promoting tumor heterogeneity, which are pivotal in tumorigenesis and development [3]. Additionally, CSCs reside in specific microenvironments and can remain dormant for extended periods, equipped with various molecular mechanisms of therapeutic resistance, rendering them insensitive to external physicochemical factors that typically kill tumor cells. It is widely accepted that CSCs are involved in cellular reprogramming during carcinogenic transformation and that pharmacological agents targeting CSCs may inhibit cancer progression and tumor self-renewal. LGR4 is widely expressed in various types of tissues, including the kidneys, skin, bones, and liver, playing significant roles in organ development, energy metabolism, bone differentiation and mineralization, immune-related diseases, and oxidative stress. Recent studies have shown that LGR4 plays a critical role in the occurrence and development of tumors, with its biological functions varying according to tumor type. Furthermore, LGR4 represents a pivotal molecule that regulates both normal and CSCs [4–8]. This review discusses the current understanding of the regulatory mechanisms of LGR4 on tumor stem cell characteristics and highlights the resistance generated by LGR4 in tumor stem cells, as well as potential therapeutic strategies. LGR4 structure and function LGR4 structure Leucine-rich repeat-containing G protein-coupled receptors (LGRs) constitute a group of transmembrane proteins that belong to the largest family of G protein-coupled receptors (GPCRs) in the human body [9]. The extracellular domains of LGRs are rich in multiple leucine repeat sequences. The leucine residues in LGRs are the primary hydrophobic residues and play a crucial role in protein-protein interactions. Based on their functions and structures, LGRs can be divided into three categories: Group A includes LGR1, which recognizes follicle-stimulating hormone, LGR2, which recognizes luteinizing hormone, and LGR3, which recognizes thyroid-stimulating hormone [10]; Group B includes the LGR4/LGR5/LGR6 receptors, which play a key role in the development of various tissues and organs and are associated with multiple cancers [11]; Group C includes LGR7 (RXFP1 receptor) and LGR8 (RXFP2 receptor), which recognize relaxin and insulin-like peptide, respectively [12]. LGR4 was first identified in 1998 and is located on human chromosome 11 (11p14.1), which is encoded by a conserved gene of 106,827 bp. The genomic structure includes 18 exons, which undergo alternative splicing to produce two isoforms, one of which encodes a protein with 951 amino acids [13–15]. Similar to other LGRs, LGR4 possesses a large extracellular domain at its N-terminus, which is capable of binding to specific ligands. This extracellular region comprises 17 leucine-rich repeat (LRR) sequences, with two regions rich in N-/C-cysteines. The seven transmembrane helices are a characteristic structural feature shared by all GPCRs, and LGR4 contains this structure as well. Specifically, it includes three extracellular loops, three intracellular loops, and a C-terminal intracellular domain [13, 15] (Fig. 1). Fig. 1The structure illustration of LGR4 protein. LGR4 was a transmembrane receptor with a N-terminal domain consists of 17 leucine-rich repeats which flanked by the N-/C- cysteine-rich regions. In addition, a seven-transmembrane domain and a C-terminal intracellular region were detected in LGR4 The structure illustration of LGR4 protein. LGR4 was a transmembrane receptor with a N-terminal domain consists of 17 leucine-rich repeats which flanked by the N-/C- cysteine-rich regions. In addition, a seven-transmembrane domain and a C-terminal intracellular region were detected in LGR4 The LGR4-related signaling pathways RSPOs/LGR4/Wnt/β-catenin signaling pathway The classical Wnt/β-catenin signaling pathway regulates the transcription of target genes by altering the cytoplasmic stability of β-catenin. Initially, LGR4 was regarded as an orphan receptor due to the absence of identified endogenous ligands [16]. It was not until 2011 that three laboratories independently identified RSPOs as the endogenous ligands for LGR4 [17–19]. RSPOs, which include RSPO1-4, are secreted proteins that primarily exert their functions via paracrine and autocrine signaling [18, 20]. The structure of RSPOs includes an N-terminal signal peptide, two cysteine-rich furin-like domains, a type 1 platelet response protein repeat sequence, and a C-terminal domain rich in basic amino acids of varying lengths, with amino acid homology among RSPO1-4 being approximately 40–60%, and structural homology also present [21, 22]. RSPOs can activate LGR 4/5/6 and induce effective and sustained activation of the Wnt pathway, which is involved in various physiological and pathological processes, including cancer [17–20]. Two hypotheses have been proposed concerning the enhancement of the Wnt/β-catenin signaling pathway by RSPOs-LGR4 interaction. One hypothesis suggests that RSPOs stimulation of LGR 4 stabilizes the Frizzled/LRP 5–6 complex in the membrane by inhibiting the activity of ZNRF 3 and RNF 43 proteins, thereby preventing their degradation [23–25]. Additionally, RSPOs may recruit the IQGAP1-DVL complex [26, 27]. Notably, recent studies have reported that RSPO2/3 can enhance or inhibit Wnt/β-catenin independently of LGR4, indicating that RSPO2/3 may regulate the Wnt signaling pathway through different mechanisms by interacting with other receptors [11, 28, 29]. Norrin/LGR4/ Wnt/β-catenin signaling pathway Following the identification of RSPOs, Norrin was recognized as another endogenous ligand of LGR4 [30]. Norrin is a secreted protein consisting of 133 residues that promotes Wnt signaling and regulates physiological processes. Structurally, Norrin possesses an N-terminal signal peptide and a C-terminal domain rich in cysteine, allowing it to form homodimeric structures. Similar to RSPOs, Norrin interacts with LGR4, stabilizing the Frizzled/LRP5-6 receptor complex, thereby enhancing Wnt/β-catenin signaling. However, in contrast to RSPOs, Norrin can interact with Frizzled receptors and enhance the Wnt pathway in an LGR4-independent manner. Additionally, Norrin can bind to LGR5/6, but it cannot activate the Wnt signaling pathway after binding to LGR5/6 [30, 31]. RANKL/LGR4/Gαq/GSK3β signaling pathway The RANKL is a newly discovered endogenous ligand of LGR4 [32]. RANKL is a homotrimeric type II membrane protein lacking a signaling peptide and belongs to the tumor necrosis factor (TNF) family of cytokines [33]. Three splice variants of RANKL have been identified: full-length RANKL (RANKL 1), a shorter form lacking part of the cytoplasmic domain (RANKL 2), and a soluble form lacking the N-terminal portion (RANKL 3) [34]. In 2016, Luo et al. first reported that RANKL binds to the extracellular domain of LGR4, activating the Gαq protein, which inhibits the GSK 3β signaling pathway, thereby suppressing the expression of the key transcription factor NFATC1 involved in osteoclastogenesis [32]. Notably, the RSPO2-LGR4 complex can also activate the Gαq and β-catenin signaling pathways, subsequently increasing the expression of the Wnt inhibitor DKK1, which promotes the formation of premetastatic niches and bone metastasis [35]. Consequently, LGR4 exerts its function through Gαq and interacts with RANKL or RSPO2. Recently, the basement membrane protein Nidogen-2 has been identified as another novel endogenous ligand of LGR4, whose selective activation of Gαq leads to the phosphorylation of PKCα-AMPKα1, thus preventing vascular calcification [36, 37]. LGR4/Gαs/cAMP/PKA/CREB signaling pathway Numerous studies have demonstrated that LGR4 promotes the transcription of several target genes via the cAMP/PKA/CREB cascade [38–43]. RSPO1 enhances ERα expression in mammary luminal cells through the LGR4/cAMP/PKA/CREB pathway [44]. Furthermore, in leukemia stem cells, RSPO2/3-LGR4 enhances Wnt/β-catenin signaling through the cAMP/PKA/CREB pathway, leading to the proliferation of leukemic stem cells and the suppression of their differentiation [6]. LGR4 in normal tissues The LGR4 gene is widely expressed in various tissues, including the adrenal gland, kidney, heart, stomach, intestine, and bone/cartilage, and is implicated in developmental processes [45]. Deletion of LGR4 results in significant prenatal and postnatal mortality in mice, underscoring the crucial of LGR4 signaling in cell survival and growth [46]. In recent years, an increasing body of literature has demonstrated that LGR4 is indispensable in processes such as embryonic development, multi-organ growth [47], energy metabolism [26, 48], ischemia/reperfusion injury [49], as well as the maintenance of stem cell self-renewal in the intestine [50], prostate [51], and mammary gland [52]. Recent studies indicate that the RSPO3-LGR4 axis plays a crucial role in cardiac development [53]. LGR4 serves as a molecular biomarker for cardiac progenitor cells [54]. In the mammary gland, LGR4 induces the expression of Sox2 through the Wnt/β-catenin/Lef1 signaling pathway, thereby facilitating mammary gland development [52]. In addition, the study found that the RSPO-LGR4/5-ZNRF3/RNF43 system regulates metabolic liver zonation via Wnt/β-catenin signaling [55]. Furthermore, LGR4 functions as a novel RANKL receptor, capable of counteract RANKL-driven osteoclastogenesis and enhance osteoblast maturation, mineralization [32], and vascular calcification [56]. LGR4 is preferentially expressed in osteoblasts and plays a significant role in the canonical Wnt signaling pathway, thereby regulating osteoblastogenesis and homeostasis [57]. LGR 4 signaling enhances Wnt signaling by binding to R-spondin, playing a functional role in stem cells self-renewal. The skin-specific deletion of LGR 4 results in a decreased number of proliferative LGR 5+ hair follicle stem cells, thereby impairing hair follicle regeneration following transplantation [58]. Silencing of the LGR 4 gene inhibits the proliferation and osteogenic differentiation of apical papilla stem cells by suppressing the Wnt/β-catenin signaling pathway [59]. Zhang et al. reported that the RSPO 3-LGR 4 system negatively regulates osteogenesis of human adipose-derived stem cells by inhibiting ERK/FGF signaling [60]. The absence of LGR 4 inhibits the differentiation of bone marrow mesenchymal stem cells (BMSCs), leading to bone mass and subsequently impairing fracture healing [61]. Luo, W.et al. identified that LGR4 promoted prostate development and stem cell differentiation by Wnt, Hedgehog and Notch1 signaling [51]. Researchers have found that LGR4, rather than LGR5, regulates mesoderm induction and hematopoietic development by modulating the transforming growth factor β (TGF-β)—SMAD2/SMAD3 signaling pathway, which is essential for hematopoietic differentiation of human pluripotent stem cells (hPSCs) [62]. LGR4 in cancer A growing body of evidence suggests that LGR4 is upregulated in cancer tissues and is associated with the occurrence, progression, and metastasis of various malignancies. Table 1 summarizes the studies that investigate the functional roles of LGR4 across different cancer types. Table 1Summary of the functional roles of LGR4 in cancersTumor typeFunction rolesPathwayRefs.Breast canerLGR4 down-regulation decreased in vitro migration and in vivo xenograft tumor growth and lung metastasisLGR4-Wnt/β-catenin signaling and EMT[4]Breast canerLGR4 interacts with EGFR and prevents EGFR ubiquitination and degradation, thereby enhancing EGFR signaling and promote breast cancer metastasisLGR4-EGFR signaling[63]Prostate cancerLGR4 knockdown exacerbated apoptosis, reduced cell viabilities, suppressed tumor growth and strengthened nuclear γH2A.X staining in AR positive PCa cells in the presence of radiationLGR4-AR/CREB1[65]Prostate cancermiR-218/LGR4 regulatory pathway in IL-6-induced cell proliferation and invasion in LNCaP-IL-6 + cellsMiR-218/LGR4-PI3K/Akt and Wnt/β-catenin signaling[66]Prostate cancerLgr4 activatesJmjd2a/AR signaling pathway to promote interaction AR with PSA promoter, causing reduction of PCa apoptosis and cell cycle arrestLGR4-Jmjd2a/AR signaling pathway[67]Prostate cancerGPCR48/LGR4 high expression promoted the migration, invasion and proliferation of the two cell lines while inhibited apoptosis in vivoLGR4-PI3K/AKT, mTOR and GSK/3β[68]Prostate cancermiR-137/LGR4 inhibited prostate cancer cell hypoxia-mediated migration and epithelial-mesenchymal transitionMiR-137-LGR4-EGFR/ERK[69]Lung adenocarcinomaKnockdown of RSPO3, LGR4, or IQGAP1 in lung cancer cell lines with Keap1 deficiency and high RSPO3-LGR4 expression led to reduction in cell proliferation, migration and tumor growth, metastasis in vitroRSPO3/LGR4-IQGAP1-Wnt signaling[71]Non-small-cell lung carcinomaMiR-449b inhibits tumor cell growth and invasion by targeting LGR4 in NSCLCMiR-449b-LGR4[73]Colorectal cancerGPR48 enhance migration and invasion of colorectal cancer cells and tumor metastasis in vivo and vitroLGR4-GSK-3β, Akt and ERK1/2-β-catenin/TCF signaling[5]colon carcinomaForced expression of GPR48 increased invasive activity and lung metastasis potency of p27-deficient HCT116 cells in vitro[74]Colorectal cancerLncGata6 promotes tumor initiation and progression by promotes the expression LGR4/5LncGata6-NURF-Ehf-LGR4/5-Wnt signaling[75]Uveal melanomaMir-34a/LGR4 inhibits the migration and invasion of uveal melanoma cellsMIR-34a-LGR4-EMT[76]Skin carcinomaLgr4 promotes skin tumor development in abnormal keratinocyte proliferation and papilloma formation of skin carcinogenesis mouse modelLGR4-MEK/ERK and Wnt/β-catenin signaling[77]Papillary Thyroid CarcinomaElevated expression of GPR48/LGR4 promoted proliferation and migration of thyroid cancer cellsR-spondin2-LGR4-MAPK/ERK1/2 and Wnt/β-catenin signaling[78]GliomaLGR4 overexpression promoted glioma cell proliferationLGR4–Wnt/β-catenin[79]OsteosarcomaStat3-LGR4 may control osteosarcoma development and progressionStat3-LGR4-Wnt/β-catenin signaling[81]Gastric cancerLGR4 was up-regulated on gastric cancer, and was significantly correlated with nodal spread[82]Serous ovarian cancerLGR4 is upregulated, and its expression is associated with recurrence free survival and overall survival in serous ovarian cancer[80]High-grade serous ovarian cancerLGR4 knockdown inhibited HGSOC cell growth and peritoneal seeding in xenograft modelsWNT7B/FZD5-LGR4/ELF3 axis[83] Table 1Summary of the functional roles of LGR4 in cancersTumor typeFunction rolesPathwayRefs.Breast canerLGR4 down-regulation decreased in vitro migration and in vivo xenograft tumor growth and lung metastasisLGR4-Wnt/β-catenin signaling and EMT[4]Breast canerLGR4 interacts with EGFR and prevents EGFR ubiquitination and degradation, thereby enhancing EGFR signaling and promote breast cancer metastasisLGR4-EGFR signaling[63]Prostate cancerLGR4 knockdown exacerbated apoptosis, reduced cell viabilities, suppressed tumor growth and strengthened nuclear γH2A.X staining in AR positive PCa cells in the presence of radiationLGR4-AR/CREB1[65]Prostate cancermiR-218/LGR4 regulatory pathway in IL-6-induced cell proliferation and invasion in LNCaP-IL-6 + cellsMiR-218/LGR4-PI3K/Akt and Wnt/β-catenin signaling[66]Prostate cancerLgr4 activatesJmjd2a/AR signaling pathway to promote interaction AR with PSA promoter, causing reduction of PCa apoptosis and cell cycle arrestLGR4-Jmjd2a/AR signaling pathway[67]Prostate cancerGPCR48/LGR4 high expression promoted the migration, invasion and proliferation of the two cell lines while inhibited apoptosis in vivoLGR4-PI3K/AKT, mTOR and GSK/3β[68]Prostate cancermiR-137/LGR4 inhibited prostate cancer cell hypoxia-mediated migration and epithelial-mesenchymal transitionMiR-137-LGR4-EGFR/ERK[69]Lung adenocarcinomaKnockdown of RSPO3, LGR4, or IQGAP1 in lung cancer cell lines with Keap1 deficiency and high RSPO3-LGR4 expression led to reduction in cell proliferation, migration and tumor growth, metastasis in vitroRSPO3/LGR4-IQGAP1-Wnt signaling[71]Non-small-cell lung carcinomaMiR-449b inhibits tumor cell growth and invasion by targeting LGR4 in NSCLCMiR-449b-LGR4[73]Colorectal cancerGPR48 enhance migration and invasion of colorectal cancer cells and tumor metastasis in vivo and vitroLGR4-GSK-3β, Akt and ERK1/2-β-catenin/TCF signaling[5]colon carcinomaForced expression of GPR48 increased invasive activity and lung metastasis potency of p27-deficient HCT116 cells in vitro[74]Colorectal cancerLncGata6 promotes tumor initiation and progression by promotes the expression LGR4/5LncGata6-NURF-Ehf-LGR4/5-Wnt signaling[75]Uveal melanomaMir-34a/LGR4 inhibits the migration and invasion of uveal melanoma cellsMIR-34a-LGR4-EMT[76]Skin carcinomaLgr4 promotes skin tumor development in abnormal keratinocyte proliferation and papilloma formation of skin carcinogenesis mouse modelLGR4-MEK/ERK and Wnt/β-catenin signaling[77]Papillary Thyroid CarcinomaElevated expression of GPR48/LGR4 promoted proliferation and migration of thyroid cancer cellsR-spondin2-LGR4-MAPK/ERK1/2 and Wnt/β-catenin signaling[78]GliomaLGR4 overexpression promoted glioma cell proliferationLGR4–Wnt/β-catenin[79]OsteosarcomaStat3-LGR4 may control osteosarcoma development and progressionStat3-LGR4-Wnt/β-catenin signaling[81]Gastric cancerLGR4 was up-regulated on gastric cancer, and was significantly correlated with nodal spread[82]Serous ovarian cancerLGR4 is upregulated, and its expression is associated with recurrence free survival and overall survival in serous ovarian cancer[80]High-grade serous ovarian cancerLGR4 knockdown inhibited HGSOC cell growth and peritoneal seeding in xenograft modelsWNT7B/FZD5-LGR4/ELF3 axis[83] Summary of the functional roles of LGR4 in cancers Breast cancer An increasing amount of evidence indicates that LGR4 is upregulated in cancer tissues and is associated with the occurrence, progression, and metastasis of various types of cancer. Overexpression of LGR4 in breast cancer is correlated with poor prognosis; patients with high LGR4 expression experience reduced overall survival, decreased distant metastasis-free survival, and lower recurrence-free survival rates [4]. Downregulation of LGR4 can inhibit Wnt signaling and epithelial–mesenchymal transition (EMT), thereby suppressing breast tumorigenesis [4]. Furthermore, Yue et al. identified a Wnt-independent LGR4-EGFR signaling axis that enhances the metastasis of breast cancer cells, which has significant implications for targeted therapy in breast cancer [63]. Prostate cancer LGR4 plays a significant role in the progression of prostate cancer. Luo et al. were the first to identify that high LGR4 expression is associated with a shorter recurrence time in prostate cancer patients [64]. After radiotherapy for prostate cancer, LGR4 expression increases, and the ablation of LGR4 inhibits the expression of AR/CREB1, thereby reducing tumor growth [65]. miR-218, a tumor-suppressing miRNA, in IL-6-induced LGR4 expression and LNCaP-IL6+ cell Proliferation and invasion [66]. Zhang et al. also revealed that LGR4 promotes Jmjd2a/AR signaling to enhance PSA transcription, contributing to the induction of prostate tumorigenesis [67]. Additionally, LGR4 can promote prostate cancer growth through the PI3K/Akt/mTOR signaling pathway [68]. Furthermore, hypoxia exposure downregulates the expression of miR-137, which targets LGR4 and inhibits prostate cancer migration and EMT by suppressing the EGFR/ERK signaling pathway [69]. Lung cancer Although LGR4 expression is low in normal adult lungs, it is significantly upregulated in both adenocarcinoma and squamous cell carcinoma of non-small cell lung cancer [70]. LGR4 is highly expressed in lung adenocarcinoma, and tumors co-expressing LGR4 and the RSPO3 ligand exhibit high invasiveness [70, 71]. LGR4 serves as an independent prognostic marker in patients with non-small cell lung cancer [72]. In Keap 1-deficient lung adenocarcinoma, RSPO3/LGR4 signaling enhances cell migration and invasion, promoting EMT by regulating IQGAP1 [71]. Yang et al. demonstrated that miR-449b inhibits tumor cell growth and invasion in NSCLC by targeting LGR4 [73]. Colorectal cancer Increasing evidence suggests that LGR4 is highly expressed in colorectal tumors, especially in advanced tumors, metastatic foci, and lymph nodes [5, 74]. Wu et al. demonstrated that LGR4 is upregulated in colorectal cancer and enhances tumor metastasis through β-catenin/TCF signaling, mediated by the PI3K/Akt and MAPK/ERK 1/2 pathways [5]. Furthermore, LncGata 6 recruits the Ehf complex to the promoter of Ehf to enhance its transcription, thereby increasing the expression of LGR 4/5 to activate Wnt signaling, which promotes the progression of colorectal cancer [75]. Skin cancer LGR4 plays a pivotal role in the onset of skin cancer and melanoma progression. It is overexpressed in melanoma cells but not in squamous cell carcinoma and other basal cell carcinomas [76, 77]. Recent studies indicate that overexpression of mir-34a reduces the expression of MMP2 regulated by LGR4, thereby diminishing the migration, invasion, and EMT of melanoma cell lines [76]. LGR4 is a key positive regulator of skin tumorigenesis, functioning by mediating the activation of the Wnt/β-catenin and MEK/ERK signaling pathways [77]. Other cancer Overexpression of LGR4 has also been documented in papillary thyroid carcinoma, glioblastoma, osteosarcoma, ovarian cancer, gastric cancer, and oral cancer [78–86]. In papillary thyroid carcinoma, both RSPO2 and LGR4 are overexpressed, and the upregulated LGR4 promotes cell proliferation and migration by inducing the MAPK/ERK1/2 and Wnt/β-catenin pathways, respectively [78]. Interestingly, high LGR4 levels can enhance glioma cell proliferation through Wnt/β-catenin activity [79]. In osteosarcoma, Liu et al. demonstrated that the overexpression of Stat3 promotes the expression of LGR4, suggesting that the Stat3-LGR4 signaling pathway may regulate the development and progression of osteosarcoma [81]. LGR4 is upregulated at both the transcriptional and translational levels in gastric cancer and is significantly associated with nodal spread [82]. Furthermore, high levels of LGR4 are associated with overall survival and disease-free survival in ovarian cancer [80], and the WNT7B/FZD5-LGR4/ELF3 axis maintains the epithelial phenotype of High-grade serous ovarian cancer (HGSOC) cells, indicating that targeting this axis may prevent the metastasis of HGSOC [83]. The mechanism of LGR4 regulation of CSC properties LGR4 expression in stem cell LGR4 is a common marker of intestinal crypt stem cells. The interaction between LGR4 and R-spondins initiates numerous Wnt-driven developmental processes, such as the formation of kidneys, eyes, or reproductive tracts, as well as the maintenance of the intestinal crypt (Paneth) stem cell pool [50]. LGR4, together with LGR5 and LGR6, are involved in the maintenance of stem cells in various tissues, such as skin [58] or intestinal tissue. LGR4 regulates the formation of kidney, intestinal, and skin epithelium [87]. LGR4 null mice exhibit intrauterine growth retardation and neonatal lethality [46], indicating its crucial role in development. LGR4 regulated the characteristics of CSCs Research indicates that LGR4 is a key molecule regulating tumor stem cells. LGR4 enhances various characteristics of tumor-initiating stem cells. Table 2 summarizes the studies investigating the role of LGR4 in CSCs across different types of cancer, while the regulatory pathway of LGR4 on CSCs is depicted in Fig. 2. Table 2Role of LGR5 in cancer stem cellsCancer stem cell typeFunction rolesPathwayRefs.AMLRSPO2/3/LGR4 upregulated key self-renewal genes and was essential for LSC self-renewal in a subset of AMLRSPO2/3-LGR4/HOXA9-wnt/β-catenin[6]Breast cancer stem cellsLGR4 deletion in MMTV-Wnt1 tumor cells or knockdown in human breast cancer cells decreased the number of functional CSCsLGR4- wnt/β-catenin and EMT[4]Breast cancer stem cellsRANKL inhibition decreased BCSC properties in LGR4-low cell lines, while it promoted migration in LGR4-high cellsRANKL/RANK-NF-ΚB-LGR4-Wnt/β-catenin signaling[89]High-grade serous ovarian cancer stem cellsWNT7B/FZD5-LGR4/ELF3 axis maintains HGSOC cell epithelial phenotype and stem-like traitsWNT7B/FZD5-LGR4/ELF3 axis[83]Tongue squamous cell carcinomaOverexpression RSPO2/LGR4 promoted stem-like properties in tongue squamous cell carcinoma both in vivo and vitroR-spodin2-LGR4- Wnt/β-catenin signaling[84]colorectal cancer stem cellsLncGata6 is required for the maintenance of cancer stem cells, which promotes the expression LGR4/5LncGata6-NURF-Ehf-LGR4/5-Wnt[75]colorectal cancer stem cellsTransplanted CD44+PrPc+LGR4+ cells effectively generated orthotopic and metastatic tumoursLGR4/PrPc- Wnt/β-catenin signaling[90]colorectal cancer stem cellsColon cancer patients with lymph nodes expression high levels of cancer stem cell markers EpCAM, LGR5 or LGR4 had a decreased mean survival time[91]Liver cancerLGR4 /EGFR signaling in hepatocellular carcinoma leads to induce tumor growth, which then contributes to stem cell characteristicsLGR4 /EGFR signaling[92] Table 2Role of LGR5 in cancer stem cellsCancer stem cell typeFunction rolesPathwayRefs.AMLRSPO2/3/LGR4 upregulated key self-renewal genes and was essential for LSC self-renewal in a subset of AMLRSPO2/3-LGR4/HOXA9-wnt/β-catenin[6]Breast cancer stem cellsLGR4 deletion in MMTV-Wnt1 tumor cells or knockdown in human breast cancer cells decreased the number of functional CSCsLGR4- wnt/β-catenin and EMT[4]Breast cancer stem cellsRANKL inhibition decreased BCSC properties in LGR4-low cell lines, while it promoted migration in LGR4-high cellsRANKL/RANK-NF-ΚB-LGR4-Wnt/β-catenin signaling[89]High-grade serous ovarian cancer stem cellsWNT7B/FZD5-LGR4/ELF3 axis maintains HGSOC cell epithelial phenotype and stem-like traitsWNT7B/FZD5-LGR4/ELF3 axis[83]Tongue squamous cell carcinomaOverexpression RSPO2/LGR4 promoted stem-like properties in tongue squamous cell carcinoma both in vivo and vitroR-spodin2-LGR4- Wnt/β-catenin signaling[84]colorectal cancer stem cellsLncGata6 is required for the maintenance of cancer stem cells, which promotes the expression LGR4/5LncGata6-NURF-Ehf-LGR4/5-Wnt[75]colorectal cancer stem cellsTransplanted CD44+PrPc+LGR4+ cells effectively generated orthotopic and metastatic tumoursLGR4/PrPc- Wnt/β-catenin signaling[90]colorectal cancer stem cellsColon cancer patients with lymph nodes expression high levels of cancer stem cell markers EpCAM, LGR5 or LGR4 had a decreased mean survival time[91]Liver cancerLGR4 /EGFR signaling in hepatocellular carcinoma leads to induce tumor growth, which then contributes to stem cell characteristicsLGR4 /EGFR signaling[92] Role of LGR5 in cancer stem cells Fig. 2The regulatory pathway of LGR4 on cancer stem cells, including RSPO2/3-LGR4-Wnt, RANKL-LGR4-Wnt, LncGata6 -LGR4-Wnt, and WNT7B/FZD5-LGR4 signaling pathway The regulatory pathway of LGR4 on cancer stem cells, including RSPO2/3-LGR4-Wnt, RANKL-LGR4-Wnt, LncGata6 -LGR4-Wnt, and WNT7B/FZD5-LGR4 signaling pathway Firstly, LGR4 is essential for the self-renewal of leukemic stem cells in patients with acute myeloid leukemia (AML). The RSPOs-LGR4 signaling pathway significantly promotes β-catenin activation and plays a critical role in the pathogenesis of AML. The aberrant activation of the RSPOs-LGR4 pathway is crucial for maintaining the self-renewal of AML stem cells, as it promotes an aggressive leukemia phenotype through a synergistic interaction with HOXA9 [6]. Naka et al. discovered that interference with the Gdpd3 gene, which encodes lysophospholipase D, significantly reduces the self-renewal capacity of chronic myeloid leukemia (CML) stem cells in vivo in mice. Interestingly, CML stem cells harboring mutations in the LGR4 subtype downstream of Gdpd3 exhibit insufficient disease-initiating ability in mice [88]. In breast CSCs, loss of LGR4 disrupts the Wnt/β-catenin signaling pathway, resulting in a reduction of SOX2+ breast CSCs and a decreased ability for tumor sphere formation [4]. Alejandro et al. indicated that the RANKL/RANK signaling pathway activates the NF-κB pathway, promoting the expansion of breast cancer CSCs. In contract, RANKL/LGR4 inhibits the Wnt pathway, blocking CSC characteristics. However, the inhibitory effect of RANKL on the regulation of breast cancer stemness varies between LGR4 and RANK. This is specifically manifested as RANKL inhibition reducing the stem cell characteristics in LGR4 low-expressing cell lines while promoting the migration of GR4 high-expressing cells [89]. Recent studies indicate that LGR4 regulates a subset of epithelial tumor stem cells in ovarian cancer. Knockdown of LGR4 inhibits the stem cell transcription factors POU5F1 and SOX2, reduces cell surface markers (CD133/ALDH1A2), and suppresses the growth and metastasis of ovarian cancer cell lines. This mechanism involves the formation of a reciprocal regulatory loop between LGR4 and the epithelial-specific transcription factor ELF3, which is positively regulated by the non-canonical Wnt signaling pathway via WNT7B/FZD5, thereby maintaining the stemness of ovarian cancer stem cell lines and promoting tumor growth and metastasis [83]. Zhang et al. suggested that the RSPO2/LGR4 signaling pathway modulates CSC characteristics in tongue squamous cell carcinoma. Tongue squamous cell carcinoma cell lines treated with RSPO2 exhibit a higher population of CSCs, express elevated levels of CSC markers, and demonstrate an increased ability for sphere formation [84]. The human ortholog LncGATA6 is highly expressed in the CSCs of colorectal cancer and promotes tumor initiation and progression. LncGata6 recruits the NURF complex to the Ehf promoter, inducing its transcription, which promotes the expression of LGR4/5 to enhance Wnt signaling activation [75]. LGR4 collaborates with CD44 and PrPc to significantly enhance the metastatic capacity of colorectal cancer CSCs, thereby maintaining stemness. CD44+PrPc+LGR4+ cells effectively develop into organoids and generat orthotopic and metastatic tumors upon transplantation. Importantly, targeting LGR4 and PrPc with lentiviral shRNAs inhibits organoid development and the growth of orthotopic tumors by suppressing Wnt/β-catenin signaling [90]. AbdelMageed et al. explored the potential of using expression levels of CSC markers EpCAM, LGR4, and LGR5 mRNA to predict survival outcomes in patients with colorectal cancer undergoing surgical treatment. During a 12-year follow-up, colorectal cancer patients with high expression levels of EpCAM, LGR4, and LGR5 in lymph nodes had a reduced average survival time [91]. The LGR4/EGFR signaling pathway in hepatocellular carcinoma leads to induce tumor growth, which then contributes to stem sell characteristics. LGR4 overexpression promotes cell proliferation, migration, and invasion, and enhances the expression of RSPO2, EGFR, β-catenin, and tumor stem cell markers CD133, CD44, whereas siLGR4 and siEGFR can inhibit biological activity [92]. Growing evidence has revealed that LGR4, by interacting with RSPOs or RANKL, enhances the Wnt/β-catenin signaling pathway to regulate cancer stem cell properties. LGR4 may also function in a Wnt/β-catenin independent manner and play distinct roles in the regulation of CSCs. However, more research is needed to fully understand the complex function of LGR4. The impact of LGR4 on tumor microenvironment The tumor microenvironment (TME) refers to the non-cancerous cells and components present within a tumor, including the molecules they produce and release. The continuous interaction between tumor cells and the TME plays a decisive role in tumor occurrence, progression, metastasis, and response to treatment [93]. Recent studies have indicated that LGR4 is associated with the regulation of immune cells in the TME. Through activation of the RSPOs-LGR4-ERK/STAT3 signaling pathway, LGR4 promotes M2 polarization of tumor-associated macrophages (TAMs). TAMs are among the most abundant infiltrating immune cells in the TME. These cells exhibit high plasticity, capable of differentiating into M1 macrophages with pro-immune activity or M2 macrophages with immunosuppressive activity, thereby facilitating tumor immune evasion [94]. Research has demonstrated that the inhibition of RSPOs-LGR4 signaling using soluble LGR4 extracellular domain (LGR4-ECD) or RSPOs neutralizing antibodies can weaken M2-TAM polarization and enhance the antitumor activity of CD8 + T cells [95]. Andel et al. discovered that multiple myeloma (MM) plasma cells express LGR4, while normal plasma cells or B cells do not. The aberrant expression of LGR4 in MM plasma cells is driven by IL-6/STAT3 signaling, enabling MM cells to hijack R-spondins produced by (pre)osteoblasts in the bone marrow microenvironment. This interaction leads to the stabilization of Wnt (co-)receptors and a significant increase in sensitivity to autocrine and paracrine Wnt signals. Thus, the abnormal R-spondin-LGR4 signaling and the resulting dysregulation of Wnt (co-)receptors are driving factors for the oncogenic Wnt/β-catenin signaling pathway in MM [96]. In recent years, the NF-κB pathway has been proposed as one of the most relevant therapeutic targets for CSCs in various types of cancers. Compelling evidence suggests that the absence of RANKL significantly reduces the CSC pool, decreases the self-renewal capacity of stem cells, and increases drug sensitivity [97, 98]. As a cytokine that activates RANK and LGR4 receptors, RANKL/RANK signaling triggers the NF-κB pathway, favoring CSC amplification, while RANKL/LGR4 signaling blocks the Wnt pathway, inhibiting the characteristics of BCSCs [89]. There is also evidence that RANKL negatively regulates RANKL signaling through the LGR4 receptor, and inhibiting RANKL may also be harmful to certain tumors [32]. Therefore, more research is needed to elucidate the complex role of RANKL/LGR4 in the tumor microenvironment. The impact of LGR4 on drug resistance in CSCs and targeted strategies The impact of LGR4 on drug resistance in CSCs CSCs can readily adapt to changes in their surrounding environment and exhibit greater resistance to conventional chemotherapy compared to other cells within tumors. The resistance of CSCs is complex and multifactorial, and it can be induced by radiotherapy and chemotherapy, persisting even after the completion of chemotherapy. Drug resistance mediated by CSCs results from a combination of intrinsic and extrinsic factors, involving mechanisms such as protective autophagy and efficient cell cycling, highly competent EMT regulators, reactive oxygen species (ROS) scavengers, drug transporters, as well as anti-apoptotic and DNA repair systems. Furthermore, the TME serves as a breeding ground that exacerbates CSCs’ resistance, as CSCs develop signaling crosstalk and share certain characteristics with other cells within the TME, complicating tumor-targeted therapies [99, 100]. One possible reason for the chemotherapy resistance associated with LGR4 and tumor stem cells is that LGR4 acts as a key receptor in the Wnt/β-catenin signaling pathway, playing a crucial role in maintaining the stemness of tumor stem cells. Activation of this pathway enhances the survival and proliferation of LGR5 + cells, leading to their resistance to chemotherapeutic agents. Sensitivity analysis of chemotherapeutic drugs and transcriptomic studies have shown that resistant patient-derived organoids (PDOs) exhibit elevated expression of LGR4 and activation of the Wnt signaling pathway, which regulates the maintenance of stem cell characteristics and plays a significant role in the resistance of colorectal cancer [90, 101]. Monoclonal antibodies targeting LGR4 can effectively block LGR4-WNT signaling transduction, and LGR4-mAb can sensitize resistant LGR4 + PDOs and tumor xenografts to chemotherapeutic agents by inducing ferroptosis [102]. In multiple myeloma, the expression of the co-receptor LGR4, the transcriptional co-activator BCL9, heparan sulfate proteoglycans (HSPGs), sumoylation of β-catenin, and mutation or deletion of the negative regulator CYLD promote aberrant activation of the Wnt pathway, mediating proliferation and contributing to drug resistance [103]. Strategies for targeting LGR4 in CSCs LGR4 promotes tumor progression through the EMT and Wnt/β-catenin pathways, with its enhanced expression associated with chemotherapy resistance and recurrence across various cancers, including breast, cervical, colorectal, gastric, hepatocellular, and ovarian cancers. LGR4 presents a potential target for therapeutic strategies aimed at overcoming chemotherapy resistance in these malignancies. The Wnt pathway, which is crucial of tumorigenesis, maintains CSC characteristics, and promotes chemotherapy resistance. Targeting Wnt signaling and CSCs offers a promising strategy for overcoming resistance this resistance. Patient-derived colorectal tumor organoids (PDOs) have been shown to recapitulate the molecular, genetic, and pathological features of the original tumors in vitro. The LGR4 monoclonal antibody (LGR4-mAb) targets the Wnt signaling pathway and can enhance ferroptosis in PDOs when used in combination with chemotherapeutic agents, providing new opportunities to combat refractory and recurrent colorectal cancer [104]. BAI, a flavonoid compound, exhibits antitumor effects against various tumors. LGR4 overexpression promotes the malignant behavior of glioma cells and facilitates tumor progression. BAI inhibits glioma cell proliferation and induces apoptosis by downregulating the LGR4-EGFR pathway, providing a novel strategy and potential therapeutic target for glioma treatment [105]. Additionally, the anti-RSPO3 antibody, rosmantuzumab (OMP-131R10) blocks the PSRO3-LGR4 interaction, impairing self-renewal and inducing differentiation in AML patient-derived xenografts, while sparing normal hematopoietic stem cells [6]. Conclusions In summary, an increasing body of evidence indicates that LGR4 is widely expressed in various tissues from early embryonic stages to adulthood. It participates in the differentiation and development of multiple organs while also being involved in immune-related diseases, metabolic disorders, and oxidative stress injuries, all the while promoting the progression of various cancers. LGR4 signaling modulates diverse cellular processes through interactions with various ligands, such as RSPOs, Norrin, and RANK. The significance of LGR4 and its ligands in the development, physiology, and maintenance of many organs has been established through various in vivo and in vitro studies. LGR4 gene knockout is associated with embryonic lethality, and surviving animals exhibit severe developmental defects in multiple organs and tissues. LGR4 is also involved in cell proliferation, survival, and differentiation in several tissues. It is associated with the progression of various cancers, as well as cell migration and invasion, primarily through the activation of the Wnt/β-catenin signaling pathway. Some studies support that inhibitors of the RSPO/LGR 4/Wnt/β-catenin axis can reduce tumor progression and metastasis. There is strong evidence that LGR4 is a key regulatory factor in CSC populations across different types of cancer. LGR4 can increase the proportion of CSCs, enhance their self-renewal capacity, and improve their sphere-forming abilities. Interestingly, disruption of the LGR4 signaling pathway leads to a reduction in the number of CSCs, decreased tumorigenesis, impaired sphere-forming ability, and weakened CSC migration and invasion. LGR4 exhibits oncogenic properties in various tumors and participates in the Wnt signaling pathway, which is associated with tumor resistance and recurrence. Several studies have suggested that inhibitors or antagonists of the RSPO/LGR4/Wnt/β-catenin axis can suppress tumor metastasis and recurrence. Despite significant progress in understanding the molecular mechanisms by which LGR4 interacts with RSPO to enhance the Wnt/β-catenin signaling pathway, numerous questions remain unresolved. For instance, the role of LGR4 through its newly discovered ligand (RANKL) in the homeostasis of various tissues and its significance in tumors remain unclear. Additionally, the endogenous ligands that activate the LGR4/cAMP/PKA signaling pathway have not yet been elucidated. Therefore, in-depth research into the mechanisms of LGR4 is crucial for revealing its spatiotemporal distribution and may open new avenues for molecularly targeted therapies for tumors and other diseases.